Host-mediated RNA Editing in Viruses

Overview

Journal Biol Direct

Publisher Biomed Central

Specialty Biology

Date 2023 Mar 28

PMID 36978112

Authors

Tongtong Zhu

Guangyi Niu

Yuansheng Zhang

Ming Chen

Chuan-Yun Li

Lili Hao

Zhang Zhang

Affiliations

Soon will be listed here.

Abstract

Viruses rely on hosts for life and reproduction, cause a variety of symptoms from common cold to AIDS to COVID-19 and provoke public health threats claiming millions of lives around the globe. RNA editing, as a crucial co-/post-transcriptional modification inducing nucleotide alterations on both endogenous and exogenous RNA sequences, exerts significant influences on virus replication, protein synthesis, infectivity and toxicity. Hitherto, a number of host-mediated RNA editing sites have been identified in diverse viruses, yet lacking a full picture of RNA editing-associated mechanisms and effects in different classes of viruses. Here we synthesize the current knowledge of host-mediated RNA editing in a variety of viruses by considering two enzyme families, viz., ADARs and APOBECs, thereby presenting a landscape of diverse editing mechanisms and effects between viruses and hosts. In the ongoing pandemic, our study promises to provide potentially valuable insights for better understanding host-mediated RNA editing on ever-reported and newly-emerging viruses.

Citing Articles

Editome Disease Knowledgebase v2.0: an updated resource of editome-disease associations through literature curation and integrative analysis.

Zhu T, Chu Y, Niu G, Pan R, Chen M, Cheng Y Bioinform Adv. 2025; 5(1):vbaf012.

PMID: 39968378 PMC: 11835235. DOI: 10.1093/bioadv/vbaf012.

BEND6 promotes RNA viruses' replication by inhibiting innate immune responses.

Chen T, Ding L, Tu S, Sun H, Zou J, Ouyang A Sci China Life Sci. 2025; .

PMID: 39821161 DOI: 10.1007/s11427-024-2698-6.

The RNA Revolution in the Central Molecular Biology Dogma Evolution.

Haseltine W, Patarca R Int J Mol Sci. 2024; 25(23).

PMID: 39684407 PMC: 11641533. DOI: 10.3390/ijms252312695.

Characterization of the symmetrical benzimidazole twin drug TL1228: the role as viral entry inhibitor for fighting COVID-19.

Murdocca M, Andrade Santos-Filho O, De Masi C, Dos Santos Rodrigues E, Campos de Souza C, De Santis R Biol Direct. 2024; 19(1):93.

PMID: 39415197 PMC: 11481581. DOI: 10.1186/s13062-024-00523-9.

Genomic Landscape and Regulation of RNA Editing in Pekin Ducks Susceptible to Duck Hepatitis A Virus Genotype 3 Infection.

Zhao H, Wu Z, Wang Z, Ru J, Wang S, Li Y Int J Mol Sci. 2024; 25(19).

PMID: 39408741 PMC: 11476845. DOI: 10.3390/ijms251910413.

References

Doria M, Neri F, Gallo A, Farace M, Michienzi A . Editing of HIV-1 RNA by the double-stranded RNA deaminase ADAR1 stimulates viral infection. Nucleic Acids Res. 2009; 37(17):5848-58. PMC: 2761272. DOI: 10.1093/nar/gkp604. View

Baumert T, Rosler C, Malim M, von Weizsacker F . Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology. 2007; 46(3):682-9. DOI: 10.1002/hep.21733. View

Khadka S, Williams C, Sweeney-Gibbons J, Basler C . Marburg and Ebola Virus mRNA 3' Untranslated Regions Contain Negative Regulators of Translation That Are Modulated by ADAR1 Editing. J Virol. 2021; 95(19):e0065221. PMC: 8428382. DOI: 10.1128/JVI.00652-21. View

Britan-Rosich E, Nowarski R, Kotler M . Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif. J Mol Biol. 2011; 410(5):1065-76. PMC: 3139112. DOI: 10.1016/j.jmb.2011.03.058. View

Li Q, Gloudemans M, Geisinger J, Fan B, Aguet F, Sun T . RNA editing underlies genetic risk of common inflammatory diseases. Nature. 2022; 608(7923):569-577. PMC: 9790998. DOI: 10.1038/s41586-022-05052-x. View

Nishikura K . Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem. 2010; 79:321-49. PMC: 2953425. DOI: 10.1146/annurev-biochem-060208-105251. View

Zhang W, Zhang X, Tian C, Wang T, Sarkis P, Fang Y . Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression. Cell Microbiol. 2007; 10(1):112-21. DOI: 10.1111/j.1462-5822.2007.01020.x. View

Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S . Dual effect of APOBEC3G on Hepatitis B virus. J Gen Virol. 2007; 88(Pt 2):432-440. DOI: 10.1099/vir.0.82319-0. View

Jin S, Choi H, Kim H, Jung Y . Human-APOBEC3G-dependent restriction of porcine endogenous retrovirus replication is mediated by cytidine deamination and inhibition of DNA strand transfer during reverse transcription. Arch Virol. 2018; 163(7):1907-1914. DOI: 10.1007/s00705-018-3822-x. View

10.

Li X, Guo F, Zhang L, Kleiman L, Cen S . APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J Biol Chem. 2007; 282(44):32065-74. DOI: 10.1074/jbc.M703423200. View

11.

Ji X, Wang H, Hao L, He W, Gao R, Li Y . Synthesis and antiviral activity of N-phenylbenzamide derivatives, a novel class of enterovirus 71 inhibitors. Molecules. 2013; 18(3):3630-40. PMC: 6270001. DOI: 10.3390/molecules18033630. View

12.

Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H . Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1 Suppl):S45-57. DOI: 10.1016/j.jhep.2014.07.027. View

13.

Azgari C, Kilinc Z, Turhan B, Circi D, Adebali O . The Mutation Profile of SARS-CoV-2 Is Primarily Shaped by the Host Antiviral Defense. Viruses. 2021; 13(3). PMC: 7999997. DOI: 10.3390/v13030394. View

14.

Ferreira A, Magalhaes A, Camoes F, Gouveia A, Vieira M, Kagan J . Hepatitis C virus NS3-4A inhibits the peroxisomal MAVS-dependent antiviral signalling response. J Cell Mol Med. 2016; 20(4):750-7. PMC: 5125814. DOI: 10.1111/jcmm.12801. View

15.

McDonnell M, Karvonen S, Gaba A, Flath B, Chelico L, Emerman M . Highly-potent, synthetic APOBEC3s restrict HIV-1 through deamination-independent mechanisms. PLoS Pathog. 2021; 17(6):e1009523. PMC: 8266076. DOI: 10.1371/journal.ppat.1009523. View

16.

Taylor D, Puig M, Darnell M, Mihalik K, Feinstone S . New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. J Virol. 2005; 79(10):6291-8. PMC: 1091666. DOI: 10.1128/JVI.79.10.6291-6298.2005. View

17.

Meshcheryakova A, Pietschmann P, Zimmermann P, Rogozin I, Mechtcheriakova D . AID and APOBECs as Multifaceted Intrinsic Virus-Restricting Factors: Emerging Concepts in the Light of COVID-19. Front Immunol. 2021; 12:690416. PMC: 8282206. DOI: 10.3389/fimmu.2021.690416. View

18.

Wang H, Zhong M, Li Y, Li K, Wu S, Guo T . APOBEC3G is a restriction factor of EV71 and mediator of IMB-Z antiviral activity. Antiviral Res. 2019; 165:23-33. DOI: 10.1016/j.antiviral.2019.03.005. View

19.

MacMillan A, Kohli R, Ross S . APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription. J Virol. 2013; 87(9):4808-17. PMC: 3624289. DOI: 10.1128/JVI.00112-13. View

20.

Maertens G, Engelman A, Cherepanov P . Structure and function of retroviral integrase. Nat Rev Microbiol. 2021; 20(1):20-34. PMC: 8671357. DOI: 10.1038/s41579-021-00586-9. View